ID: MRFR/HC/6265-CR | July 2019 | Region: Global | 145 pages
Market Overview
The Global Duloxetine Intermediate & Atorvastatin Intermediates Market is expected to register a CAGR 4.04% to reach USD 73.5466 million by 2023. Duloxetine intermediate is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is widely approved for the treatment of stress urinary incontinence in women, major depressive disorder (MDD), and other chronic diseases. The atorvastatin intermediate is commonly used in lowering the cholesterol level and helps prevent cardiovascular diseases.
Rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, rising incidence of chronic diseases are expected to enhance the market growth. However, factors such as increasing healthcare cost and unfavorable drug price control policies across various countries may restrain the market growth during the forecast period.
Market Dynamics
The global duloxetine intermediate & atorvastatin intermediates market has been primarily driven by the rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, and growing incidence of chronic diseases. For instance, as per the survey carried out by the American Heart Association and the American College of Cardiology in 2016, around 37.5% (43.2 million) to 48.6% (56 million) of the US adults were on treatment by atorvastatin intermediate. Factors such as rising healthcare cost, unfavorable drug price control policies across various countries may restrain the market growth during the forecast period.
Global Duloxetine Intermediate & Atorvastatin Intermediates Market Revenue, by Intermediate, 2017 & 2023 (USD Million)
Sources: MRFR Analysis
Segmentation
The global duloxetine intermediate & atorvastatin intermediates market is segmented into an intermediate type. Based on intermediate, the market is bifurcated into duloxetine intermediates and atorvastatin intermediates. Duloxetine Intermediate segment held a market share of 32393.03 USD Million in 2017.
Key Players
The prominent players in the global Duloxetine Intermediate & Atorvastatin Intermediates market are Jiangxi Aifeimu Technology Co., Ltd, Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Jigs Chemicals, Manus Aktteva, Arch Pharmalabs, Afine Chemicals Ltd, Shodhana Laboratories, Fluorochem Ltd, Chiral Bio Sciences Ltd, Tokyo Chemical Industry Co., Ltd.
Asia-Pacific Duloxetine Intermediate & Atorvastatin Intermediates Market Share, 2017 (%)
Sources: MRFR Analysis
Regional Analysis
The global duloxetine intermediate & atorvastatin intermediates market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas accounts the largest market share, wherein North America is expected to dominate the market mainly due to the increasing geriatric population and the availability of advanced healthcare facilities in this region.
Europe is anticipated to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are well-established healthcare infrastructure and the increase in adoption of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disease and major mental disorders.
Asia-Pacific is estimated to be the fastest-growing region in the global duloxetine intermediate & atorvastatin intermediates market. This can be attributed to developing economies such as China, India, and South Korea emerging as major destinations for the outsourcing of clinical trials, drug manufacturing, and pathology testing. Japan held a market share of 18.5% in 2017.
Also, the duloxetine intermediate & atorvastatin intermediates market in the Middle East and Africa region is projected to account for the least share during the review period. The Middle East is expected to influence the market owing to the increasing use of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disorders in Saudi Arabia, Kuwait, and the UAE.
Market Segmentation
Global Duloxetine Intermediate & Atorvastatin Intermediates Market, by Intermediate Type
Duloxetine Intermediates
Atorvastatin Intermediates
Global Duloxetine Intermediate & Atorvastatin Intermediates Market, by Region
Americas
North America
US
Canada
Latin America
Europe
Western Europe
Germany
UK
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
Middle East
Africa
Available Additional Customizations
Intended Audience
Duloxetine intermediate & atorvastatin intermediates manufacturers
Healthcare providers
Research institutes and academic centers
Government associations
Market research and consulting
Frequently Asked Questions (FAQ) :
Duloxetine intermediate and atorvastatin intermediates market is projected to grow at a 4.04% CAGR between 2015-2023.
The Americas is expected to dominate the duloxetine intermediate and atorvastatin intermediates market.
Duloxetine intermediate and atorvastatin intermediates market is predicted to touch USD 73.5466 million by 2023.
The duloxetine intermediates segment will lead the duloxetine intermediate and atorvastatin intermediates market.
Rising healthcare cost may restrict duloxetine intermediate and atorvastatin intermediates market growth.